Search the Newsreel

Replimune Group, Inc. (REPL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz announced that investors who suffered losses with Replimune Group, Inc. (REPL) have the opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that between October 20, 2025, and April 10, 2026, Replimune made false …

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

Pomerantz LLP has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) for alleged securities fraud. The lawsuit comes after the FDA rejected Replimune's Biologics License Application for RP1, citing several deficiencies in its studies, leading to significant drops in the company's …

ORI issuer (NYSE: ORI) insider plans 1,788-share sale after prior disposal

An insider at Old Republic International Corp. (NYSE: ORI), Carolyn Monroe, plans to sell 1,788 shares of common stock on August 11, 2026, valued at approximately $75,560.88. This sale is related to a stock option exercise and follows a previous disposal of 13,330 shares …

Replimune Group, Inc. (REPL) stock price, news, quote and history

This Yahoo Finance page provides a comprehensive overview of Replimune Group, Inc. (REPL) stock, including its current price, news headlines, and performance data. The stock is listed on NasdaqGS and shows recent fluctuations based on FDA decisions regarding its drug candidates. News articles detail …

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) for alleged securities fraud. The lawsuit, covering the period from October 20, 2025, to April 10, 2026, claims Replimune made misleading statements by failing to disclose …

Repco Home Finance Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

UBS Adjusts Republic Services Price Target to $235 From $233, Maintains Neutral Rating

UBS has increased its price target for Republic Services (RSG) to $235 from $233, while maintaining a Neutral rating on the stock. This adjustment reflects a modest upward revision in their valuation of the waste management company. The news comes amid other analyst updates …

Repay Holdings Corp (RPAY) Stock Earnings Transcripts

Why (IRS) Price Action Is Critical for Tactical Trading

This article analyzes the price action of Irsa Inversiones Y Representaciones S.a. (NYSE: IRS), highlighting a weak near-term sentiment challenging long-term strength. It presents institutional trading strategies including long, breakout, and short positions, along with multi-timeframe signal analysis. The report identifies an exceptional 51.5:1 …

Replimune Prices $150 Million Underwritten Offering

(RTTNews) - Replimune Group, Inc. (REPL), a commercial-stage biotechnology company developing oncolytic immunotherapies, announced the pricing of an underwritten offering of 9,701,490 shares of its common stock at $12.06 per share. In addition, the company is issuing pre-funded warrants, equal to the offering price …

Technical Reactions to IPI Trends in Macro Strategies

Intrepid Potash Inc (IPI) is exhibiting a mid-channel oscillation pattern with strong near-term sentiment potentially leading to a long-term positive bias. AI models have generated distinct trading strategies including position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss levels. The …

Dimensional Fund Advisors LP Reduces Holdings in Repay Holdings Corporation $RPAY

Dimensional Fund Advisors LP reduced its stake in Repay Holdings Corporation (NASDAQ:RPAY) by 17.8% in Q1 2026, selling over 638,000 shares but still retaining a significant holding. Institutional investors collectively own 82.73% of RPAY. The company's stock shows mixed analyst sentiment with a consensus …

Dimensional Fund Advisors LP Sells 121,412 Shares of Sarepta Therapeutics, Inc. $SRPT

Dimensional Fund Advisors LP significantly reduced its stake in Sarepta Therapeutics, Inc. by selling 121,412 shares, leaving them with 336,736 shares valued at $7.3 million. Despite institutional investors owning a large portion of the company and some increasing their positions, analyst sentiment is mixed, …

Sarepta Therapeutics, Inc. (SRPT) Investor Outlook: Analyzing The 31.63% Potential Upside

Sarepta Therapeutics (SRPT) is a biotechnology firm focusing on RNA-targeted therapeutics and gene therapies for rare diseases like Duchenne muscular dystrophy, with a market capitalization of $1.77 billion. Despite a revenue decline of 34.30% and negative EPS, analysts project a 31.63% potential upside, driven …

Republic Healthcare's Market Cap Drops To HK$76m Leaving Insiders With Losses

Repligen Corporation (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by Brokerages

Repligen Corporation (NASDAQ:RGEN) has received a "Moderate Buy" consensus rating from eighteen brokerages, with an average 12-month price target of $166.43. The company recently surpassed quarterly earnings and revenue expectations, reporting $0.54 EPS and $204.13 million in revenue, an 11.9% year-over-year increase. Despite a …

Republic Airways Holdings Ord Shs (RJET) Earnings Forecast: Future EPS & Revenue Growth Estimates

Redwire, Enphase, Core & Main, Republic Services, and Owens Corning Stocks Trade Up, What You Need To Know

Redwire, Enphase, Core & Main, Republic Services, and Owens Corning Stocks Trade Up, What You Need To Know What Happened? A number of stocks jumped in the afternoon session after the July jobs report showed an unexpected loss of 23,000 jobs, signaling a cooling …

Repay Holdings Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:RPAY) 2026-08-10

Repay Holdings Corporation (RPAY) reported strong Q2 2026 earnings, with revenue of $100.7 million, a 33.2% increase year-over-year, and exceeding estimates. Despite rising costs and a net loss of $11.0 million, the company showed significant growth in gross profit and operating cash flow. Insider …

Repay Holdings (RPAY) Meets Q2 Earnings Estimates

Repay Holdings Corporation (RPAY) Stock Rises on Q2 2026 Earnings

Repay Holdings Corporation (RPAY) reported strong Q2 2026 earnings, with revenue of $100.7 million, a 33.2% increase year-over-year, and exceeding estimates. Despite rising costs and a net loss of $11.0 million, the company showed significant growth in gross profit and operating cash flow. Insider …

Repay (NASDAQ:RPAY) Posts Earnings Results, Misses Estimates By $0.01 EPS

Repay Holdings (NASDAQ: RPAY) boosts revenue, leverages up to fund KUBRA buy

IMS Strategic Income Fund's Old Republic International Corp(ORI) Holding History

This article details IMS Strategic Income Fund's historical holdings in Old Republic International Corp (ORI). As of December 31, 2025, the fund held 5,200 shares valued at $237,330, representing 12.44% of its stock portfolio. Despite an average purchase price of $43.42 per share, the …

Repligen Shares Surge 16.2% as Record Revenue Offsets Shrinking Q2 Margins

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made false and misleading statements regarding its …

Replimune Group stock hits 52-week high at 13.92 USD

Replimune Group stock has reached a 52-week high of $13.92, driven by a 128% one-year return and recent FDA accelerated approval for its cancer treatment TUDRIQEV. While analysts have upgraded the stock and increased price targets, InvestingPro suggests the shares may be overvalued, and …

Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months

Replimune Group's stock has surged nearly 223% in the past three months, primarily due to the FDA's accelerated approval of its lead oncolytic immunotherapy, RP1 (Tudriqev), for advanced melanoma. This approval, in combination with Bristol Myers' Opdivo, marks a significant commercial milestone for Replimune …

Replimune prices $150M underwritten offering of common stock and pre-funded warrants

Replimune (REPL) has priced an underwritten offering to raise approximately $150.0 million in gross proceeds. The offering includes 9,701,490 shares of common stock and pre-funded warrants for 2,736,340 shares, priced at $12.06 per share. Net proceeds are estimated to be around $140.5 million after …

Repligen Corporation (RGEN) Stock Analysis: A Healthcare Standout with 13.3% Potential Upside

Repligen Corporation (RGEN) is analyzed as a strong player in the healthcare sector, specifically medical instruments and supplies, with a current market cap of $9.25 billion and a potential upside of 13.3% according to analysts. The company shows promising revenue growth, positive analyst sentiment …

Republic Services, Inc. $RSG Shares Sold by NewEdge Advisors LLC

NewEdge Advisors LLC significantly reduced its stake in Republic Services, Inc. (NYSE:RSG) by 40.5% in the first quarter, selling 33,841 shares. Despite this, other institutional investors have increased their positions, with institutional ownership collectively at 57.73%. Republic Services exceeded Q2 earnings and revenue estimates, …

IRSA Inversiones y Representaciones SA (IRS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Repro India Consolidated June 2026 Net Sales at Rs 139.91 crore, up 20.13% Y-o-Y

Why Sarepta Therapeutics (SRPT) Is Up 12.9% After Cutting 2026 Guidance And Naming A New CEO

Sarepta Therapeutics' stock rose 12.9% despite cutting its 2026 revenue guidance to US$1.20 billion–US$1.30 billion and reporting lower Q2 2026 revenue of US$401.25 million, alongside a net loss. The company appointed Michael Severino, M.D., as the new CEO, a move seen as a positive …

Repligen (RGEN) Is Up 16.2% After Revenue Rises But Profitability Compresses In Q2 2026

In July 2026, Repligen Corporation reported second-quarter 2026 results showing revenue of US$204.13 million versus US$182.37 million a year earlier, while net income fell to US$5.01 million from US$14.87 million and diluted EPS from continuing operations decreased to US$0.09 from US$0.26. Over the six-month …

Telkom Indonesia (Persero) Tbk PT (TLK) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Telkom Indonesia (Persero) Tbk PT (TLK), highlighting its strong earnings forecast score of 10.00 and ranking 1st in the Telecommunications Services industry. Analysts have set an average price target of $24.10, with one analyst recommending a "Strong …